Potential options for managing LOX+ ER− breast cancer patients

Overexpression of lysyl oxidase (LOX) is often observed in estrogen receptor negative (ER–) breast cancer patients with bone metastasis. In the present bioinformatics study, we observed that LOX is a prognostic factor for poor progression free survival in patients with ER– breast cancer. LOX overexp...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Yong, Lian, Shenyi, Cui, Xingran, Meng, Kexin, Győrffy, Balázs, Jin, Tao, Huang, Dongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078060/
https://www.ncbi.nlm.nih.gov/pubmed/27147578
http://dx.doi.org/10.18632/oncotarget.9073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078060/
https://www.ncbi.nlm.nih.gov/pubmed/27147578
http://dx.doi.org/10.18632/oncotarget.9073

Ejemplares similares